Literature DB >> 21161707

The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?

Jacques Barbet, Jean-François Chatal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21161707     DOI： 10.1007/s00259-010-1707-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  11 in total

1.  177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.

Authors:  Christof Seidl; Christine Zöckler; Roswitha Beck; Leticia Quintanilla-Martinez; Frank Bruchertseifer; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

2.  [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

Authors:  Mikael Persson; Lars Gedda; Hans Lundqvist; Vladimir Tolmachev; Hans Nordgren; Per-Uno Malmström; Jörgen Carlsson
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

Authors:  Jörgen Elgqvist; Håkan Andersson; Tom Bäck; Ingela Claesson; Ragnar Hultborn; Holger Jensen; Bengt R Johansson; Sture Lindegren; Marita Olsson; Stig Palm; Elisabet Warnhammar; Lars Jacobsson
Journal:  J Nucl Med       Date:  2006-08       Impact factor: 10.057

4.  Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.

Authors:  Michael R Zalutsky; David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; Roger E McLendon; Terence Z Wong; Darell D Bigner
Journal:  J Nucl Med       Date:  2007-12-12       Impact factor: 10.057

5.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

6.  Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.

Authors:  Manuel J Koppe; Robert P Bleichrodt; Annemieke C Soede; Albert A Verhofstad; David M Goldenberg; Wim J G Oyen; Otto C Boerman
Journal:  J Nucl Med       Date:  2004-07       Impact factor: 10.057

7.  Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.

Authors:  J Schlom; K Siler; D E Milenic; D Eggensperger; D Colcher; L S Miller; D Houchens; R Cheng; D Kaplan; W Goeckeler
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

8.  213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.

Authors:  Roswitha Beck; Christof Seidl; Birgit Pfost; Alfred Morgenstern; Frank Bruchertseifer; Hannsjörg Baum; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Sci       Date:  2007-06-11       Impact factor: 6.716

9.  Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Authors:  Marcus P Kelly; Sze Ting Lee; F-T Lee; Fiona E Smyth; Ian D Davis; Martin W Brechbiel; Andrew M Scott
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

10.  Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.

Authors:  Birgit Pfost; Christof Seidl; Michael Autenrieth; Dieter Saur; Frank Bruchertseifer; Alfred Morgenstern; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  J Nucl Med       Date:  2009-10       Impact factor: 10.057
View more
  5 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Ming-De Lu; Dian-Chao Yue; Xiao-Yan Xie; Guang-Jian Liu
Journal:  Cancer Biother Radiopharm       Date:  2013-08-21       Impact factor: 3.099

3.  The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Le-Hang Guo; Lin-Na Liu; Feng Lu
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

4.  Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.

Authors:  Sophie E Eriksson; Tom Bäck; Erika Elgström; Holger Jensen; Rune Nilsson; Sture Lindegren; Jan Tennvall
Journal:  EJNMMI Res       Date:  2013-04-04       Impact factor: 3.138

5.  Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.

Authors:  Caroline Bodet-Milin; Ludovic Ferrer; Amandine Pallardy; Thomas Eugène; Aurore Rauscher; Jacques Barbet; Françoise Kraeber-Bodéré
Journal:  Front Oncol       Date:  2013-07-11       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.